Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags
I wrote recently about how political pressure on FDA Commissioner Stephen Hahn in 2020 may have helped the Texas firm Direct Biologics move their product ExoFlo forward inside the agency. Today I analyze the ExoFlo Phase I clinical trial paper used in that push on Hahn to get the firm the IND for a Phase II […]
Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags Read More »